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Abstract
Background: Punica granatum (pomegranate), an edible fruit originating in the Middle East, has been used as a
traditional medicine for treatment of pain and inflammatory conditions such as peptic ulcer. The numerous risks
associated with nonsteroidal anti-inflammatory drugs (NSAIDs) for treatment of pain and inflammation give rise to
using medicinal herbs as alternative therapies. This study aimed to evaluate the anti-inflammatory effect of isolated
compounds from the ethyl acetate (EtOAc) fraction of P. granatum by determination of their inhibitory effects
on lipopolysaccharide (LPS), stimulated nitric oxide (NO), prostaglandin E2 (PGE-2), interleukin-6 (IL-6) and
cyclooxxgenase-2 (COX-2) release from RAW264.7 cells.
Methods: The compounds ellagic acid, gallic acid and punicalagin A&B were isolated from EtOAc by high
performance liquid chromatography (HPLC) and further identified by mass spectrometry (MS). The inhibitory
effect of ellagic acid, gallic acid and punicalagin A&B were evaluated on the production of LPS-induced NO
by Griess reagent, PGE-2 and IL-6 by immunoassay kit and prostaglandin E2 competitive ELISA kit, and COX-2
by Western blotting.
Results: Ellagic acid, gallic acid and punicalagin A&B potentially inhibited LPS-induced NO, PGE-2 and IL-6
production.
Conclusion: The results indicate that ellagic acid, gallic acid and punicalagin may be the compounds
responsible for the anti-inflammatory potential of P. granatum.
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Background
Inflammatory diseases such as arthritis, asthma, allergic
rhinitis and eczema have increased throughout the world
and are treated with conventional anti-inflammatory drugs
such as steroidal anti-inflammatory drugs and NSAIDs
[1]. However, their prolonged use may produce severe side
effects which may sometimes be lethal [2].
Therefore, it is important to develop novel and organic
anti-inflammatory agents with minimal adverse effects.
Pomegranate fruits are widely consumed worldwide. In
Libya, it is traditionally regarded as a life giving fruit and
used to treat conditions such as gastric ulcers. Anti-
inflammatory potential of different varieties of pomegran-
ate has been reported [3–5]. More interestingly, a recent
study reported that the extract of pomegranate pro-
duced gastro protection along with its anti-inflammatory
effect [6].
Apart from its anti-inflammatory potential, pomegran-
ate also earned its medicinal value with a number of
proven potentials like anti-lipoperoxidation [7], anti-ulcer
[8, 9], and anti-oxidation [10, 11]. Another phenomenal
potential of pomegranate is attenuating neurogenic pain
[12]. Pomegranate could successfully attenuate tibial and
sural nerve transection (TST) induced behavioral alter-
ations, including cold, mechanical and heat hyperalge-
sia; dynamic mechanical allodynia and cold allodynia.
The same study demonstrated a significant reduction in
tumor necrosis factor alpha (TNF-α) [12]. Furthermore,
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pomegranate is useful in minimizing conditions like
cancer [13]. Ellagic acid, gallic acid and punicalagin
A&B isolated from the EtOAc fraction of the ethanol
whole fruit extract have been investigated for their po-
tential inhibitory effects in vitro using LPS-stimulated
macrophages. LPS is a potent activator of macrophages,
which produce a variety of pro-inflammatory mediators
such as NO, PGE-2 and interleukins [14–16].
LPS is one of the best characterized stimuli to induce
up-regulation of pro-inflammatory proteins such as COX-
2 and inducible NO. Inducible COX-2 is responsible for
the high prostaglandin levels observed in inflammatory
pathology. A number of inflammatory stimuli such as LPS
and pro-inflammatory cytokines activate immune cells to
up-regulate such inflammatory states. Therefore, these
stimuli are useful targets in the development of new anti-
inflammatory drugs [17, 18].
Although there are previous reports on anti-
inflammatory effect of P.granatum the exact compounds
involved have not been identified yet. Therefore, the
objective of the present study was to study the effect
of gallic acid, ellagic acid and punicalagin isolated




Fresh pomegranate fruits, P. granatum from Libya, were
collected in the fall of 2010 from an orchard in the
region of Tripoli, Libya. The sample was identified by
Professor AbdulRazag Sheriff, a taxonomist from the
Faculty of Science, University of Tripoli. A voucher spe-
cimen number 01563 was deposited at the Herbarium at
University of Tripoli.
Chemicals and reagents
All chemicals used were of analytical grades, with purity
(determined by GC) of minimum 99.0%, unless other-
wise specified. Ethanol, HPLC-grade methanol and
sulphuric acid (98%) were purchased from RCI Labscan
(Thailand). Phosphoric acid (HPLC-grade, 85–90%) were
purchased from Sigma FLUKA (Germany). Bradford
reagent, griess reagent, (modified), L-glutamine, LPS
(E.coli) and sodium pyruvate were purchased from
Sigma (USA). RAW264.7 (ATCC® TIB-71™) cells were
purchased from ATCC (USA). Dulbecco’s Modified Eagle
Medium (DMEM), 2-[4-(2-Hydroxyethyl)-1-piperazinyl]
ethanesulfonic Acid (HEPES) and Penicillin-Streptomycin
Mixed Solution (Stabilized) were purchased from Nacalai
Tesque (Japan). Fetal bovine serum (FBS) was purchased
from JR Scientific Inc. (USA). Cell Titer 96® Nonradioac-
tive Cell Proliferation Assay kit was purchased from
Promega (USA). IL-6 (mouse) enzyme immunoassay kit
was purchased from Cayman (USA).
Mammalian protein extraction reagent (M-PER) and
PGE-2 competitive ELISA kit were purchased from
Thermo Fisher Scientific Inc. (USA). Complete protease
inhibitor cocktail tablets were purchased from Roche
(Germany). Antibodies against COX-2 and beta actin
were purchased from Abnova (Taiwan). DAB substrate
was purchased from Rockland (USA).
Extraction method
Pomegranate extract fractions were prepared as de-
scribed by Ben Saad and Kim KH [19]. The whole fruits
were washed with water and fruits with cuts were
discarded, then the fruits were freeze-dried and ground
into dry powder using a Waring blender. Then the pow-
der was dried in an oven at 40 °C for 24 h. The powder
was sieved through 24 mesh filter. The resultant powder
of 1 kg was extracted with 2500 mL of 80% ethanol in
water at room temperature for 24 h in a shaking water
bath and filtered with whatman filter paper. The ethanol
was removed by using RV10 rotary evaporator (IKA,
Guangzhou, China) and the resultant residue was 110 g
of crude ethanol pomegranate extract (EPE) yield 11%.
Approximately, 100 g of crude EPE was mixed with
200 mL of n-hexane to dissolve the non-polar com-
pounds. The mixture was filtered with whatman filter
paper and the filtrate was concentrated by the rotary
evaporator yielding the hexane fraction. The hexane
insoluble residue was subjected to partitioning between
the ethyl acetate and distilled water (immiscible solvents)
using a separatory funnel. The ethyl acetate was re-
moved using rotary evaporator and the water was re-
moved by a freeze dryer to give the EtOAc fraction
and the water fraction. The amount of EtOAc fraction
was 42.2 g yield 3.5%.
Phytochemical analysis
Isolation and structure identification of ellagic acid and
punicalagin A&B from EtOAc by HPLC and MS analysis with
spectrometry
The EtOAc sample was prepared and run on Shimadzu
HPLC with UV detector. Standards were used to estab-
lish the retention time of interest. Pomegranate ethyl
acetate extract (500 mg) was loaded in preparative
HPLC. The standard and sample of interest were sepa-
rated on a Luna Phenyl Hexyl, 250 × 4.6 mm, 5 um col-
umn was employed at ambient temperature using the
following method mobile Phase A: 0.1 formic acid in
water, mobile phase B: 100% methanol with the follow-
ing gradient 0.01–3 min, A95%, B5%, 15–20 min A50%
B50%, 25 min, A 10% B90%, 27–30 min A95% B5% with
the flow rate 1.0 mL/min, injection volume 10.0 μL. The
identification of ellagic acid and punicalagin A&B was
made by comparing to standards. LC-MS Waters was
used for mass detection. Gallic acid was isolated from
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EtOAc by another method previously reported by Ben
Saad and Kim, 2015 [19].
Cell culture
Frozen RAW264.7 cells were cultured in dulbecco’s high
Glucose modified Eagles medium (DMEM) supple-
mented with 10% of FBS, 4 mM l-glutamine, 110 mg/L
sodium pyruvate, 25 mM HEPES, 100 U/mL of penicillin
and 100 μg/mL of streptomycin. Cells were maintained
in an incubator at 37 °C with 5% CO2 and 95% humidity
until 80% confluent was achieved in 75 cm2 flasks. The
culture medium was replaced every 3 days. Subcultures
were prepared by scraping as per recommended by
ATCC. For use in cell culture experiments, the isolated
compounds, ellagic acid, gallic acid and punicalaginA&B
from EtOAc were prepared in DMEM with 1% DMSO.
To study the dose–response relationship four doses 50,
100, 150 and 200 μg/mL were used. These doses were
selected based on literature [20] and tests in our labora-
tory. Cell culture treated with each isolated compound
plus LPS and LPS alone were analyzed.
Cell viability assay
The cell viability was carried out using the CellTiter
96® Nonradioactive Cell Proliferation Assay kit accord-
ing to the manufacturer’s instructions. In brief, cells
were seeded at 5 × 104 cells/well in 160 μL of complete
culture medium into a 96-well, flat-bottom cell culture
plate, and incubated overnight. Twenty microliter of
each isolated compound were then being added into
the wells to final concentrations of 0, 50, 100, 150 and
200 μg/mL in triplicate, 2 h before addition of 20 μL
LPS to a final concentration of 1 μg/mL, and incubated
for another 24 h (end point of treatment). Fifteen
microliter of pre-warmed dye solution was added into
each well and further incubated for 4 h. At the end of
incubation, the wells were mixed with 100 μL of the
solubilization solution/stop mix solution. One hour
later the absorbance was read using a 96-well plate
reader at wavelength of 570 nm against reference wave-
length of 690 nm.
Measurement of nitrite production
RAW264.7 cells were cultured in 96-well plates at 5 × 104
cells/well and were treated for 24 h with each isolated
compound (50–200 μg/mL) plus LPS (1 μg/mL) or LPS
alone. For measurement of nitrite in culture media, Griess
reagent (modified) was used. In brief, at the end point of
treatment, 100 μl of cell culture medium of each well was
collected and mixed with equal volume of 1× Griess re-
agent and incubated for 15 min in the dark then the ab-
sorbance at 540 nm was measured in a 96-well plate
reader. Fresh culture medium was used as the blank.
Measurements of IL-6 and PGE-2 production
RAW264.7 cells were cultured and treated with each iso-
lated compound plus LPS or just LPS as mentioned
above. Culture media were collected at 6 h and 24 h
post-LPS stimulation for IL-6 and PGE-2 measurements,
respectively. Both IL-6 and PGE-2 in culture media were
separately quantitated with IL-6 (mouse) enzyme im-
munoassay kit and PGE-2 competitive ELISA kit accord-
ing to the manufacturers’ instructions.
Measurement of COX-2 production
RAW264.7 cells were cultured in 24-well plates at 5 ×
105 cells per well and were treated for 24 h with each
isolated compound as previously mentioned. Cell lysate
was prepared with M-PER and added to complete prote-
ase inhibitor cocktail tablet. The total protein concentra-
tion of cell lysate was determined by Bradford method
using a protein assay kit. COX-2 production was mea-
sured from cell lysate using western blot approaches
with anti-beta actin antibody as loading control [21].
Cell lysates were electrophoresed by SDS-PAGE, trans-
ferred to nitrocellulose membrane and then probed with
anti-COX-2 antibodies at a dilution of 1:2000 in TBST
for 3 h at room temperature followed by overnight incu-
bation in 4 °C. Subsequently, the membrane was washed
thoroughly and incubated with a secondary antibodies
conjugated with HRP. The membrane was again washed
thoroughly with and developed in DAB substrate for
detection of bands.
Statistical analysis
Each experiment was repeated at least three times and
the results were expressed as mean ± SD. Statistical sig-
nificances were compared between each treated group
and analyzed by the using Dunnett’s post test of one way
ANOVA and Tukey Kramer test keeping LPS: 1 ug/mL
+ isolate: 0 ug/mL as control. All graphs were generated
using Graph Pad Prism 5.0 and data p < 0.05, p < 0.01
and p < 0.001 were considered significant and marked
with *, ** and *** respectively.
Results
Phytochemical screening
The EtOAc fraction showed the presence of ellagic acid
67 mg/g collected at RT = 22.6 min, and punicalagin
A&B 52 mg/g collected at RT = 14.1 min (Figs. 1 and 2).
The punicalagin mass spectra was 1083 in negative
mode and ellagic acid mass spectra was 301 in negative
mode (Figs. 3 and 4). These results are consistent with a
previous study in which pomegranate juice polyphenols
were identified using different experimental conditions
[22]. It has also been reported that the single charge m/z
1083 ion was detected for punicalagin A&B and a single
of charge m/z 301 ion was detected for ellagic acid [19].
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Gallic acid was collected at RT = 17 min and mass spec-
tra was 169 in negative mode as previously reported by
BenSaad and Kim, 2015 [19].
In this study, the isolated ellagic acid, gallic acid and
punicaligin A&B were also examined for their effects on
LPS-induced inflammation of the RAW264.7 cells. First,
the cytotoxic effect of ellagic acid, gallic acid and punica-
ligin A&B on RAW264.7 cells were evaluated using the
cell viability assay. MTT assay results for ellagic acid,
gallic acid and punicaligin A&B showed a decrease in
the cell viability (Fig. 5). The percentage of viable cells
decreased, with a minimum of 87% survival, which still
correlates to the non-toxic category. If 80% or higher
survival rate shown in MTT reaction, it is determined
that there is no cytotoxicity [23].
To investigate the effect of ellagic acid, gallic acid and
punicalagin A&B on NO production, we measured the
accumulation of nitrite, a stable oxidized product of NO
in culture media by using Griess reagent method [23].
Nitrite production was examined in RAW264.7 cells
stimulated with LPS in the presence or absence of ellagic
acid, gallic acid and punicalagin A&B (50, 100, 150,
200 μg/mL) for 24 h. The nitrite production was inhib-
ited by ellagic acid, gallic acid and punicalagin A&B
treatments in a concentration–dependent manner (Fig. 6,
and it was observed that three isolated compounds
caused maximum inhibition of nitrite production at a
concentration of 200 μg/ml) However, the highest inhib-
ition effect was detected with ellagic acid in comparison
to other two compounds.
The immune response to some inflammatory stimuli
is known with the production of PGE-2 and interleu-
kins therefore, we examined the effects of ellagic acid,
gallic acid and punicalagin A&B on PGE-2 and IL-6
productions. The expressions of PGE-2 and IL-6 were
measured in the medium of RAW264.7 cells cultured
with LPS (1 μg/mL) in the presence or absence of iso-
lated compounds (50, 100, 150, 200 μg/ml) for 24 h in
case of PGE-2 and 6 h in case of IL-6. PGE-2 and IL-6
produced and released into the culture medium was
assayed by ELISA method. As shown in (Figs. 7 and 8)
ellagic acid, gallic acid and punicalagin A&B suppressed
Fig. 1 HPLC chromatogram of ethyl acetate fraction showing the presence of punicalagin A&B collected at 14.1 min
Fig. 2 HPLC chromatogram of ethyl acetate fraction showing the presence of ellagic acid collected at 22.6 min
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LPS-induced PGE-2 and IL-6 production in a dose
concentration-dependent manner.
We further evaluated the effect of ellagic acid,
gallic acid and punicalagin A&B on LPS-induced
COX-2 gene expression in macrophages. The expres-
sion of COX-2 protein was measured in RAW264.7
cells exposed to LPS (1 μg/ml) for 24 h. Ellagic acid,
gallic acid and punicalagin A&B did not suppress
LPS-induced COX-2 expression. Western blotting
band intensities were expressed as relative density
compared to the untreated controls and measured by
Image J software (National Institute of Health, US)
(Fig. 9).
Discussion
Feldmann and Kim research teams reported in 2008
that inflammation is a complex process regulated by a
cascade of cytokines, growth factors, NO and prostaglan-
dins produced by activated macrophages [24–26]. During
inflammation, macrophages play a central role in the man-
agement of many different immunopathological phenom-
ena, including the overproduction of pro-inflammatory
cytokines and inflammatory mediators such as IL-1B, IL-
6, NO, iNOS, COX-2 and TNF-alpha [24–26]. Our results
showed that, ellagic acid, gallic acid and punicalagin A&B
suppressed the levels of NO, PGE-2, IL-6 production in
LPS-induced RAW264.7 cells.
Nitric oxide is a proinflammatory mediator that induces
inflammation due to excessive production in pathological
or abnormal physiological situations [27]. The synthesis of
macrophage NO synthase enzyme, which generates NO
from arginine is induced by LPS [28]. The increase in pro-
duction of NO is harmful to the affected tissue, and may
lead to acute or chronic inflammation [29]. Therefore, NO
Fig. 3 Mass spectrum showing the presence of punicalagin A&B [M-H] -m/z 1083.43
Fig. 4 Mass spectrum showing the presence of ellagic acid [M-H] -m/z 301
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production inhibition in inflammation has a potential
therapeutic significance. A previous study has reported
that punicalagin isolated from a Chinese variety of
P.granatum suppressed NO production in RAW267.4
cells stimulated macrophages [20]. Our study did confirm
that punicalagin A&B effectively decreased NO produc-
tion using the same cell line. In addition, we have
shown in this study that ellagic acid and gallic acid
reduced NO production in RAW267.4 cells treated
with LPS.
Fig. 5 Cell viability was determined from the 24 h culture of cells stimulated with LPS (1 μg/mL) in the presence of ellagic acid, gallic acid and
punicalagin The data represent mean ± SD of n = 3, *p < 0.05,**p < 0.01 vs LPS treated control
Fig. 6 Effect of ellagic acid, gallic acid and punicalagin on nitrite production in LPS-stimulated RAW264.7 cells. The cells were stimulated with 1 μg/mL
of LPS only or with LPS plus various concentrations (50, 100, 150, 200 μg/mL) of gallic acid for 24 h. Nitrite production was determined by the Griess
reagent method. The data represent the mean ± SD of n = 3, *** p < 0.001, vs #LPS treated control* means significant difference by Tukey Kramer test
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Fig. 7 Effect of ellagic acid, gallic acid and punicalagin on PGE-2 production in LPS-stimulated RAW264.7 cells. The cells were stimulated with
1 μg/ml of LPS only or with LPS plus various concentrations (50, 100, 150, 200 μg/mL) of ellagic acid, gallic acid and punicalagin n = 3,
***p < 0.001 vs #LPS treated control* means significant difference by Tukey Kramer test
Fig. 8 Effect of ellagic acid, gallic acid and punicalagin on IL-6 production in LPS-stimulated RAW264.7 cells. The cells were stimulated
with 1 μg/ml of LPS only or with LPS plus various concentrations (50, 100, 150, 200 μg/mL) of for ellagic acid, gallic acid and punicalagin
6 h. IL-6 produced and released into the culture medium was assayed by ELISA method. The data represent the mean ± SD of n = 3, *** p < 0.001 vs
#LPS treated control* means significant difference by Tukey Kramer test
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The isolated compounds ellagic acid, gallic acid and
punicalagin A&B inhibited the PGE-2 production dose
dependently.
COX-2 is an enzyme that generates prostaglandins,
which is induced by proinflammatory cytokines and
other activators, such as LPS, resulting in the release of
a large amount of PGE2 at inflammation sites. There-
fore, identification of COX-2 inhibitors is considered to
be a promising approach to protecting against inflamma-
tion. In this study we found that isolated compounds el-
lagic acid, gallic acid and punicalagin A&B inhibited the
PGE-2 production dose dependently. A recent study on
punicalagin [30] produced similar findings.
Another recent study reported that punicalagin medi-
ated inhibition of PGE2 production in LPS-stimulated
macrophage cells was associated with down regulation
of COX-2 proteins [31].
However, in our study COX-2 protein expression of
LPS-induced RAW264.7 cells was not affected after
treatment with the ellagic acid, gallic acid and punicala-
gin A&B for 24 h. Similar findings has been reported
when four isolated compounds namely, punicalagin,
punicalin, strictinin A and granatin B which were hydro-
lysable tannins from P. granatum did not reduce COX-2
protein expression after treatment for 18 h [20]. How-
ever, in the same study punicalagin was reported to
inhibit COX-2 expression after treatment period of 8 h.
Their findings have indicated that punicalagin may in-
hibit the enzyme at an early stage but not a late stage.
IL-6 has been proven to be a key player in chronic in-
flammation, and IL-6 levels are elevated in inflammatory
diseases in humans [32]. In this research project, the
three isolated compounds gallic acid, ellagic acid and
punicalagin effectively decreased IL-6 dose dependently.
Importantly, this agrees with a recent study where inves-
tigators isolated punicalagin and showed that punicala-
gin did reduce IL-6 levels in LPS induced macrophages
[30]. The present study is the first showcasing the anti-
inflammatory effects of isolated ellagic acid and gallic
acid from P. granatum. However, scientific, evidence
shows that ellagic acid and gallic acid from different
sources other than P. granatum did inhibit NO, PGE-2
and IL-6 in different systems [29, 33, 34].
The results of the present study showed the anti-
inflammatory potential of P. granatum. EtOAc was able
to significantly, inhibit the inflammatory mediators NO,
PGE2, and IL-6. The three isolated compounds ellagic
acid, gallic acid and punicalagin A&B inhibited NO,
PGE2, and IL-6 in LPS – induced RAW 267.4 macro-
phages. Therefore, we postulate that ellagic acid, gallic
acid and punicalagin A&B may be the compounds
responsible for P.granatum anti-inflammatory effect.
Recent studies have reported the antiinflammatory effect
of punicalagin [20, 30, 31] yet we are first to report the
Fig. 9 Effect of ellagic acid, gallic acid and punicalagin on the activation of COX-2 in the LPS-stimulated RAW264.7 cells. RAW264.7 cells were
stimulated with LPS (1 μg/mL) in ellagic acid, gallic acid and punicalagin A&B (50, 100, 150, 200 μg/mL) for 24 h. Whole-cell lysates were subjected
to 10% SDS-PAGE and expression of COX-2 and β-actin were determined by western blotting. Band intensities were expressed as relative density
compared to LPS control. The figure is representative of three similar experiments
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antiinflammatory effect of gallic acid and ellagic acid,
whether these compounds work as sole agents or have a
synergistic effect still remains a question.
Further studies, are required to investigate the com-
bination of ellagic acid gallic acid and punicalagin activ-
ity and also to investigate whether other compounds
are involved in its anti-inflammatory effect. According
to our results, we suggest that P. granatum (pomegranate)
is a nutraceutical with a well-defined anti-inflammatory
potential.
Conclusion
The results obtained in this study clearly indicate that el-
lagic acid, gallic acid and punicalagin A&B isolated from
P. granatum inhibited the production of NO, PGE2, and
IL-6 in LPS–induced RAW267.4 macrophages. There-
fore, we postulate that ellagic acid, gallic acid and puni-
calagin A&B may be the compounds responsible for the
anti-inflammatory effect of P. granatum. However, there
are some limitations in this study; positive controls have
not been used. In addition, there are still differences be-
tween in vitro and in vivo system during agent testing
which make it not totally reliable. Therefore, further
studies are required to indicate if the results obtained in
our study are relevant to human health.
Abbreviations
COX-2: Cyclooxygenase-2; EtOAc: Ethyl acetate fraction of P.granatum; IL-
6: Interleukin-6; LPS: Lipopolysaccharide; NO: Nitrous oxide; PGE: Prostaglandin- E
Acknowledgments
A special thanks and appreciation for Dr. Abdulbaset Yagoubi from
Agriculture and Agri-Food Canada for revising and editing the manuscript.
Funding
This work has been sponsored by University of Malaya through
postgraduate research grant (PV151/2012A) and University of Malaya
Research Grant (RG 334-15AFR).
Availability of data and materials
Data are all contained within the paper.
Authors’ contributions
LAB: Participated in the design of the study, prepared the ethyl acetate
fraction, performed both the HPLC-MS analysis and cell culture experiments
and drafted the paper. KHK supervised the work on HPLC-MS analysis, and
corrected the manuscript for publication. CCQ and WRK assisted in the cell
culture experiments. MS supervised the work on the cell culture experiments.
All authors have read and approved final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The fresh pomegranate fruit, P. granatum was identified by Professor
AbdulRazag Sheriff, a taxonomist from the Faculty of Science, University of
Tripoli. A voucher specimen number 01563 was deposited at the Herbarium
of the same University. This study used cell lines commercially available,
thereby not requiring the ethics. The consent to participate is not applicable
in this study.
Author details
1Department of Physiology, Faculty of Medicine, Malaysia Institute of Medical
Research, Kuala Lumpur 50603, Malaysia. 2University College Lincoln, Petaling
Jaya 47301, Malaysia. 3Malaysia Institute of Medical Research, Kuala Lumpur
50603, Malaysia.
Received: 4 August 2015 Accepted: 5 January 2017
References
1. Gautam R, Jachak SM. Recent developments in antiinflammatory natural
products. Med Res Rev. 2009;29(5):767–820.
2. Pountos I, Georgouli T, Bird H, Giannoudis PV. Nonsteroidal anti-
inflammatory drugs: prostaglandins, indications, and side effects. Int J
Interferon Cytokine Mediator Res. 2011;3:19–27.
3. Olapour S, Najafzedeh H. Evaluation analgesic, anti-inflammatory and
antiepletic effect of hydro alcoholic peel extract of Punica granatum
(pomegranate). Asian J Med Sci. 2010;2(6):266–70.
4. Ouachrif A, Khalki H, Chaib S, Muntassir M, Abufatima R, Farouk L, Benharraf
A, Chait A. Comparitive study of the anti-inflammatory and antinociceptive
effects of two varieties of Punicagranatum. Pharm Biol. 2012;50(4):429–38.
5. Shukla M, Gupta K, Rasheed Z, Khan KA, Haqqi TM. Bioavailable
constituents/metabolites of pomegranate (Punica granatum L) prefentially
inhibit COX-2activity exvivo and IL-I beta induced PGE2 production in
human chondrocytes in vitro. J Inflammation. 2008;5:9.
6. Gonzalez-Trujano ME, Pellicer F, Mena P, Monerno DA, Garcia-Viguera C.
Antinociceptive and anti-inflammatory activities of a pomegranate
(Punica granatum L.) extract rich in ellagitannins. Int J Food Sci Nutr.
2015;66(4):395–9.
7. Reddy MK, Gupta SK, Jacob MR, Khan SI, Ferreira D. Antioxidant, antimalarial
and antimicrobial activities of tannin-rich fractions, ellagitannins and
phenolic acids from Punica granatum L. Planta Med. 2007;73(5):461–7.
8. Ajaikumar KB, Asheef M, Babu BH, Padikkala J. The inhibition of gastric
mucosal injury by Punica granatum L. (Pomegranate) methanolic extract.
J Ethnopharmacol. 2005;96:171–6.
9. Labib RM, El-Ahmady SH. Antinociceptive, anti-gastric ulcerogenic and anti-
inflammatory activities of standardized Egyptian pomegranate peel extract.
Journal of Applied Pharmaceutical Science. 2015;5(1):48–51.
10. Gil MI, Tomas Barberan FA, Hess-Pierce B, Holcroft DM, Kader AA.
Antioxidant activity of pomegranate juice and its relationship with phenolic
composition and processing. J Agric Food Chem. 2000;48:4581–9.
11. Lantzourakia DL, Sinanogloub VJ, Zoumpoulakisc P, Proestos C. Comparison
of the antioxidant and antiradical activity of pomegranate (Punica
granatum L.) by ultrasound-assisted and classical extraction. Anal Lett.
2016;49(7):969–78.
12. Jain V, Pareek A, Bhardwaj YR. Attenuating effect of standardized fruit
extract of Punica granatum L in rat model of tibial and sural nerve
transection induced neuropathic pain. BMC Compl and Alt Med.
2013;13:274.
13. Lansky EP, Newman RA. Punica granatum (pomegranate) and its
potential for prevention and treatment of inflammation and cancer.
J Ethnopharmacol. 2007;109(2):177–206.
14. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. Molecular
mechanisms of macrophage activation and deactivation by
lipopolysaccharide:roles of the receptor complex. Pharmacol Thera.
2003;100(2):171–94.
15. Laskin DL, Sunil VR, Gardner CR, Laskin JD. Macrophages and tissue injury:
agents of defence or destruction? Annu Rev Pharmacol Toxicol.
2011;51:267–88.
16. Kuroda E, Yamashita U. Mechanisms of enchanced macrophage mediated
prostaglandin E2 production and its suppressive role in Th1 and Th2
dominant BALB/C mice. J Immunol. 2003;170:757–64.
17. Zeihofer HU, Brune K. Analgesic strategies beyond the inhibition of A.
Trends Pharmacol Sci. 2006;27:467–74.
18. Jachak SM. PGE synthase inhibitors as an alternative to COX-2 inhibitors.
Curr Opin Investig Drugs. 2007;8:411–41.
19. Ben Saad LA, Kim KH. Phytochemical constituents and analgesic activity of
ethyl acetate fraction of Punicagranatum L (Punicaceae). Trop J Pharm Res.
2015;14(1):87–93.
20. Lee CJ, Chen LG, Liang WL, Wang CC. Antiinflammatory effects of Punica
granatum Linne invitro and invivo. Food Chem. 2010;118(2):315–22.
BenSaad et al. BMC Complementary and Alternative Medicine  (2017) 17:47 Page 9 of 10
21. Chun SC, Jee SY, Lee SG, Park SJ, Lee JR, Kim SC. Anti-inflammatory activity
of the methanol extract of moutan cortex in LPS-Activated Raw 264.7 Cells.
Evid Based Complement Alternat Med. 2007;4(3):327–33.
22. Mena P, Calani L, Dall’Asta C, Galaverna G, García-Viguera C, Bruni R., …Del
Rio, D. Rapid and comprehensive evaluation of (Poly) phenolic compounds
in pomegranate (Punica granatum L.) juice by UHPLC-MSn. Molecules.
2012;17:14821–40.
23. Panichayupakaranan P, Tewrakul S, Yuenyongsawad S. Antibacterial anti-
inflammatory and antiallergic activities of standardized pomegranate rind
extract. Food Chem. 2010;123(2):400–3.
24. Feldmann M. Many cytokines are very useful therapeutic targets in disease.
J Clin Invest. 2008;118:3533–353617.
25. Feldmann M, Brennan D, Chantry C, Haworth M, Turner P, Katsikis M, Londei E,
Abney G, Buchan K, Barett A, Corcoran MK, Issonerghis R, Zheng B, Grubeck-
Loebenstein D, Barkley CQ, Chu MF, Maini RN. Cytokine assays role in evaluation
of the pathogenesis of autoimmunity. Immunol Rev. 1991;119:105–23.
26. Kim EY, Moudgil KD. Regulation of autoimmune inflammation by pro-
inflammatory cytokines. Immunol Lett. 2008;120(1–2):1–5.
27. Sharma JN, Al-Omran A, Parvathy SS. Role of nitric oxide in inflammatory
diseases. Inflammopharmacology. 2007;15(6):252–9.
28. Lowenstein CJ, Alley EW, Raval P, Snowman AM, Syder SH, Russel SW,
Murphy WJ. Macrophage nitric oxide synthase gene:Two upstream regions
mediate induction by interferon V and lipopolysaccaride. Proc Natl Acad Sci.
1993;90:9730–5.
29. Kim AR, Cho JY, Zou Y, Choi JS, Chung HY. Flavonoids differentially
modulate nitric oxide production pathways in lipopolysaccharide-activated
RAW264.7 cells. Arch Pharm Res. 2005;28:297–304.
30. Xu X, Yin P, Wan C, Chong X, Liu M, Cheng P, Chen J, Liu F, Xu J.
Punicalagin inhibits inflammation in LPS-induced RAW264.7 macrophages
via the suppression of TLR4-mediated MAPKs and NF-κB activation.
Inflammation. 2014;37(3):956–65.
31. Olajide OA, Kumar A, Velagapudi R, Okorji UP, Fiebich BL. Punicalagin
inhibits neuroinflammation in LPS-activated rat primary microglia. Mol Nutr
Food Res. 2014;58(9):1843–51.
32. Gabby C. Interleukin-6 and chronic inflammation. Arthritis Res Ther.
2006;8 Suppl 2:S3.
33. Huangi GJ, Huangi MH, CHI CS, Huangi S, Shie PH, Yen MT, Wang BS.
Analgesic and anti-inflammatory activities of aqueous extracts of Fructus
ligustri lucidi. J Food Drug Anal. 2012;20(3):617–27.
34. Karlsson S, Nåmberg E, Fjaeraa C, Wijkander J. Ellagic acid inhibits
lipopolysaccharide-induced expression of enzymes involved in the synthesis
of prostaglandin E2 in human monocytes. Br J Nutr. 2010;103:1102–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
BenSaad et al. BMC Complementary and Alternative Medicine  (2017) 17:47 Page 10 of 10
